Products

Bosentan is a non-selective antagonist of endothelin ETA and ETB receptors. Bosentan reduces both pulmonary and systemic vascular resistance, resulting in increased cardiac output without increasing heart rate (HR). Endothelial neurohormone-1 (ET-1) is one of the most potent of the currently known vasoconstrictors, which also has the ability to stimulate fibrosis, cell proliferation, cardiac hypertrophy and remodeling, and also exhibits anti-inflammatory activity. These effects are induced when endothelin-1 (ET-1) binds to ETA and ETB receptors located in the endothelium and vascular smooth muscle cells. Concentrations of ET-1 in tissues and plasma are elevated in several cardiovascular and connective tissue diseases, including pulmonary arterial hypertension (PAH), scleroderma, acute and chronic heart failure, myocardial ischemia, systemic hypertension, and atherosclerosis, suggesting that ET-1 is involved in the pathogenesis of these diseases. In LAH and heart failure, in the absence of antagonism to endothelin receptors, elevated ET-1 concentrations strictly correlate with the severity and prognosis of these diseases.

Manufacturer

JSC Pharmasyntez

Show contacts